Vivian I. Avelino-Silva, Philippe Mayaud, Adriana Tami, Maria C. Miranda, Kerstin D. Rosenberger, Neal Alexander, Luis Nacul, Aluisio Segurado, Moritz Pohl, Sarah Bethencourt, Luis A. Villar, Isabelle F. T. Viana, Renata Rabello, Carmen Soria, Silvia P. Salgado, Eduardo Gotuzzo, María G. Guzmán, Pedro A. Martínez, Hugo López-Gatell, Jennifer Hegewisch-Taylor, Victor H. Borja-Aburto, Cesar Gonzalez, Eduardo M. Netto, Paola M. Saba Villarroel, Bruno Hoen, Patrícia Brasil, Ernesto T. A. Marques, Barry Rockx, Marion Koopmans, Xavier de Lamballerie, Thomas Jaenisch & the ZIKAlliance Clinical Study Group
The European Commission (EC) Horizon 2020 (H2020)-funded ZIKAlliance Consortium designed a multicentre study including pregnant women (PW), children (CH) and natural history (NH) cohorts. Clinical sites were selected over a wide geographic range within Latin America and the Caribbean, taking into account the dynamic course of the ZIKV epidemic. Results of these large cohort studies will provide better risk estimates for birth defects and other developmental abnormalities associated with ZIKV infection including possible co-factors for the variability of risk estimates between other countries and regions. Additional outcomes include incidence and transmission estimates of ZIKV during and after pregnancy, characterization of short and long-term clinical course following infection and viral kinetics of ZIKV.